Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGC001 in Predicted Severe Acute Pancreatitis
NCT07803965Phase 2Recruiting
- Sponsor
- Sungen Biomedical
- Start
- Sep 2026
- Primary completion
- Nov 2027
- Countries
- 1
01
Overview
A Phase 2 trial of SGC001 in acute pancreatitis (AP), sponsored by Sungen Biomedical. Started Sep 2026; status: recruiting.
02
Drugs
SGC001
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on NCT07803965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803965.